title: Authors' reply.
authors.forename: Li Tao
authors.initials: LT
authors.lastname: Zhang
authors.forename: Sung Won
authors.initials: SW
authors.lastname: Lee
authors.forename: Kwangsung
authors.initials: K
authors.lastname: Park
authors.forename: Woo Sik
authors.initials: WS
authors.lastname: Chung
authors.forename: Sae Woong
authors.initials: SW
authors.lastname: Kim
authors.forename: Jae Seog
authors.initials: JS
authors.lastname: Hyun
authors.forename: Doo Geon
authors.initials: DG
authors.lastname: Moon
authors.forename: Sang-Kuk
authors.initials: SK
authors.lastname: Yang
authors.forename: Ji Kan
authors.initials: JK
authors.lastname: Ryu
authors.forename: Dae Yul
authors.initials: DY
authors.lastname: Yang
authors.forename: Ki Hak
authors.initials: KH
authors.lastname: Moon
authors.forename: Kweon Sik
authors.initials: KS
authors.lastname: Min
authors.forename: Jong Kwan
authors.initials: JK
authors.lastname: Park
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D059411:Lower Urinary Tract Symptoms / Q000188:drug therapy*; D008297:Male; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D011799:Quinazolines / Q000627:therapeutic use*; D064804:Urological Agents / Q000627:therapeutic use*
chemical_list: D000959:Antihypertensive Agents; D011799:Quinazolines; D064804:Urological Agents